Evofem Biosciences, Inc. provided sales guidance for the fiscal year 2022. For the year, the company expects net product sales will be in the range of $30 million to $35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0129 USD | -4.85% | -16.77% | -79.84% |
05-16 | Transcript : Evofem Biosciences, Inc. - Special Call | |
05-15 | Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-79.84% | 966K | |
+42.69% | 749B | |
+34.11% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+18.08% | 248B | |
-3.44% | 214B | |
+11.35% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Biosciences, Inc. Provides Sales Guidance for the Fiscal Year 2022